...
首页> 外文期刊>Scientifica >The Role of the Dysfunctional Akt-Related Pathway in Cancer: Establishment and Maintenance of a Malignant Cell Phenotype, Resistance to Therapy, and Future Strategies for Drug Development
【24h】

The Role of the Dysfunctional Akt-Related Pathway in Cancer: Establishment and Maintenance of a Malignant Cell Phenotype, Resistance to Therapy, and Future Strategies for Drug Development

机译:功能性Akt相关途径在癌症中的作用:恶性细胞表型的建立和维持,对治疗的抗性以及药物开发的未来策略

获取原文
           

摘要

Akt serine/threonine kinases, or PKB, are key players in the regulation of a wide variety of cellular activities, such as growth, proliferation, protection from apoptotic injuries, control of DNA damage responses and genome stability, metabolism, migration, and angiogenesis. The Akt-related pathway responds to the stimulation mediated by growth factors, cytokines, hormones, and several nutrients. Akt is present in three isoforms: Akt1, Akt2, and Akt3, which may be alternatively named PKBα, PKBβ, and PKBγ, respectively. The Akt isoforms are encoded on three diverse chromosomes and their biological functions are predominantly distinct. Deregulations in the Akt-related pathway were observed in many human maladies, including cancer, cardiopathies, neurological diseases, and type-2 diabetes. This review discusses the significance of the abnormal activities of the Akt axis in promoting and sustaining malignancies, along with the development of tumor cell populations that exhibit enhanced resistance to chemo- and/or radiotherapy. This occurrence may be responsible for the relapse of the disease, which is unfortunately very often related to fatal consequences in patients.
机译:Akt丝氨酸/苏氨酸激酶或PKB是调节多种细胞活动(例如生长,增殖,免受凋亡损害,控制DNA损伤反应和基因组稳定性,代谢,迁移和血管生成)的关键参与者。 Akt相关途径可响应生长因子,细胞因子,激素和多种营养素介导的刺激。 Akt存在三种同工型:Akt1,Akt2和Akt3,可以分别将其分别称为PKBα,PKBβ和PKBγ。 Akt同工型编码在三个不同的染色体上,其生物学功能主要不同。在许多人类疾病中都观察到Akt相关途径的失调,包括癌症,心脏病,神经系统疾病和2型糖尿病。这篇综述讨论了Akt轴异常活动在促进和维持恶性肿瘤中的重要性,以及发展出对化学疗法和/或放射疗法具有增强抵抗力的肿瘤细胞群的发展。这种情况可能是疾病复发的原因,不幸的是,这种疾病经常与患者的致命后果有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号